The new dengue vaccine, developed by the Japanese laboratory Takeda Pharma, will be available for application in Brazil starting this week. Dubbed Qdenga (TAK-003), the immunizer is the first released in the country for people who have never had contact with the disease and will be offered in private clinics.
read more:
According to the Brazilian Association of Vaccine Clinics (ABCVAC), the cost of applying the vaccine should vary between R$ 350 and R$ 500, depending on the state. In São Paulo, for example, the Maximum Consumer Price (PMC) authorized by the National Health Surveillance Agency (Anvisa) for clinics is R$ 379.40.
The registration of Qdenga was approved in March of this year, being applied in two doses, with an interval of three months. The immunizer, with an effectiveness of 80.2%, is indicated for children over four years old and people up to 60 years old and can be applied to citizens who have already been infected by the virus.
+ Anvisa warns about poisoning by mixing cleaning products
From January to June this year, 1,379,983 cases of dengue have already been registered in Brazil, with 635 deaths, an increase of 22% compared to the same period last year. The increase happened in the middle of the rainy season, which helps the proliferation of the transmitting mosquito, the Aedes aegypti, when there is standing water.
The new dengue vaccine, developed by the Japanese laboratory Takeda Pharma, will be available for application in Brazil starting this week. Dubbed Qdenga (TAK-003), the immunizer is the first released in the country for people who have never had contact with the disease and will be offered in private clinics.
read more:
According to the Brazilian Association of Vaccine Clinics (ABCVAC), the cost of applying the vaccine should vary between R$ 350 and R$ 500, depending on the state. In São Paulo, for example, the Maximum Consumer Price (PMC) authorized by the National Health Surveillance Agency (Anvisa) for clinics is R$ 379.40.
The registration of Qdenga was approved in March of this year, being applied in two doses, with an interval of three months. The immunizer, with an effectiveness of 80.2%, is indicated for children over four years old and people up to 60 years old and can be applied to citizens who have already been infected by the virus.
+ Anvisa warns about poisoning by mixing cleaning products
From January to June this year, 1,379,983 cases of dengue have already been registered in Brazil, with 635 deaths, an increase of 22% compared to the same period last year. The increase happened in the middle of the rainy season, which helps the proliferation of the transmitting mosquito, the Aedes aegypti, when there is standing water.
